FASN and lung carcinoma: In addition to anti-FASN activity, (−)-epigallocatechin-3-gallate (EGCG) has been shown to suppress the growth and induce apoptosis of lung cancer without producing an undesirable effect on carnitine palmitoyl transferase I (CPT-1) and β-oxidation activities which result in a severe decrease of body weight as reported in C75-treated animals [34].